HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
Villacampa G, Pascual T, Tarantino P, Cortés J, Perez-García J, Llombart-Cussac A, Conte P, Mancino M, Guarneri V, Dieci MV, Waks AG, Schettini F, Brasó-Maristany F, Griguolo G, de Castro BA, Reboredo C, Antolín S, Bueno-Muiño C, Echavarría I, López-Tarruella S, Massarrah T, Del Monte-Millán M, Martín M, Buckingham W, Parker JS, Vivancos A, Polyak K, Filho OM, Wolff AC, DeMichele A, Tung NM, Perou CM, Paré L, Villagrasa P, Prat A, Tolaney SM.
Villacampa G, et al. Among authors: de castro ba.
Lancet Oncol. 2025 Aug;26(8):1100-1112. doi: 10.1016/S1470-2045(25)00276-1. Epub 2025 Jul 14.
Lancet Oncol. 2025.
PMID: 40675165